FLT3 and acute myeloid leukemia: Midostaurin is currently the only tyrosine kinase inhibitor (TKI) that has demonstrated superior results compared to standard intensive therapy in younger FLT3-mutated newly diagnosed AML patients for all survival endpoints, including overall survival [11].